| PRECLINICAL | evidence | Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements. | Semaglutide | — | 2026-04-28 |
| PRECLINICAL | evidence | FDA Approves Higher-Dose Injectable Semaglutide. | Semaglutide | — | 2026-04-28 |
| PRECLINICAL | evidence | Blamed but not at fault: Anti-obesity medication adverse effects misidentified as perioperative complications - a comprehensive review and medicolegal warning for anesthesiologists. | Semaglutide | — | 2026-04-28 |
| PRECLINICAL | evidence | Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide. | Semaglutide | — | 2026-04-28 |
| PRECLINICAL | evidence | Assessment of Carbon Emission Impact of Semaglutide in Patients With Type 2 Diabetes in the United Kingdom Using an Innovative Modeling Approach. | Semaglutide | — | 2026-04-28 |
| PRECLINICAL | evidence | Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review. | Semaglutide | — | 2026-04-25 |
| PRECLINICAL | evidence | GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis. | Semaglutide | — | 2026-04-25 |
| PRECLINICAL | evidence | Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' reply. | Semaglutide | — | 2026-04-25 |
| PRECLINICAL | evidence | Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial. | Semaglutide | — | 2026-04-25 |
| PRECLINICAL | evidence | Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial. | Semaglutide | — | 2026-04-25 |
| PRECLINICAL | evidence | Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study). | Semaglutide | — | 2026-04-24 |
| PRECLINICAL | evidence | Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study. | Semaglutide | — | 2026-04-24 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 and atrial fibrillation incidence: Associations independent of weight loss. | Semaglutide | — | 2026-04-23 |
| PRECLINICAL | evidence | Retinal Outcomes in Diabetes: Antihyperglycemic Therapy, EWDR, and Perioperative Considerations. | Semaglutide | — | 2026-04-23 |
| PRECLINICAL | evidence | LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. | Semaglutide | Muscle growth & preservation | 2026-04-22 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review. | Semaglutide | — | 2026-04-22 |
| PRECLINICAL | evidence | Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study. | Semaglutide | — | 2026-04-21 |
| PRECLINICAL | evidence | Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions. | Semaglutide | — | 2026-04-21 |
| PRECLINICAL | evidence | Leucine supplementation modulates body composition and early weight rebound during GLP-1 receptor agonist therapy in diet-induced obese mice. | Semaglutide | — | 2026-04-20 |
| PRECLINICAL | evidence | Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5. | Semaglutide | — | 2026-04-20 |
| PRECLINICAL | evidence | Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles. | Semaglutide | — | 2026-04-20 |
| PRECLINICAL | evidence | Influence of pH, Buffering Capacity, Ionic Strength, Bile Salts, and Model Drugs on Micellization Behaviour of Salcaprozate Sodium in Physiological Range pH Buffers. | Semaglutide | — | 2026-04-20 |
| PRECLINICAL | evidence | Semaglutide Prevents Aortic Rupture and Dissection in the Angiotensin II Mouse Model. | Semaglutide | — | 2026-04-20 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists in the Management of Mitochondrial Diabetes in an Adolescent: A Case Report. | Semaglutide | — | 2026-04-18 |
| PRECLINICAL | evidence | Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study. | Semaglutide | Weight & fat loss | 2026-04-18 |
| PRECLINICAL | evidence | Maternal cytomegalovirus serology results by geographic region in a large multicenter United States study. | Wegovy | — | 2026-04-18 |
| PRECLINICAL | evidence | Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes. | Semaglutide | — | 2026-04-17 |
| PRECLINICAL | evidence | Correction: Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways. | Semaglutide | — | 2026-04-17 |
| PRECLINICAL | evidence | Childhood Obesity, Medications, and Surgeries. | Semaglutide | — | 2026-04-16 |
| PRECLINICAL | evidence | Complex clinical encounter series: Glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health? | Semaglutide | — | 2026-04-16 |
| PRECLINICAL | evidence | Hemodynamic Changes in Response to GLP-1 Treatment in ICD and CRT Patients: Insights From HeartLogic Sensor Data. | Semaglutide | — | 2026-04-16 |
| PRECLINICAL | evidence | Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities. | Semaglutide | — | 2026-04-16 |
| PRECLINICAL | evidence | Widespread exposure to GLP-1RAs and weight loss-related discourse: Considering potential public health implications. | Semaglutide | — | 2026-04-15 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonist Semaglutide and SGLT2 Inhibitors after Acute Coronary Syndrome in Patients with Diabetes: Real-World Comparative Outcomes from an Observational Registry. | Semaglutide | — | 2026-04-14 |
| PRECLINICAL | evidence | Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass. | Semaglutide | — | 2026-04-13 |
| PRECLINICAL | evidence | In brief: Rybelsus R2 rebranded as Ozempic. | Ozempic | — | 2026-04-13 |
| PRECLINICAL | evidence | Assessment of knowledge, attitude, and practices towards the usage of antidiabetic drugs for weight loss among Lebanese population. | Semaglutide | — | 2026-04-13 |
| PRECLINICAL | evidence | Weight "regain" in obesity shifts responsibility from biology to personal inadequacy. | Semaglutide | — | 2026-04-13 |
| PRECLINICAL | evidence | Genetic variants show link to patients losing more weight when taking Wegovy and Mounjaro. | Wegovy | — | 2026-04-13 |
| PRECLINICAL | evidence | Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes. | Semaglutide | Weight & fat loss | 2026-04-13 |
| PRECLINICAL | evidence | Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation. | Semaglutide | — | 2026-04-10 |
| PRECLINICAL | evidence | Oral Health Considerations and Dental Management Guidelines for Semaglutide Medications. | Semaglutide | — | 2026-04-10 |
| PRECLINICAL | evidence | Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials. | Semaglutide | — | 2026-04-10 |
| PRECLINICAL | evidence | MASH and liver fibrosis: Clinical trials to watch. | Semaglutide | Liver health | 2026-04-10 |
| PRECLINICAL | evidence | Is Oral Semaglutide a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective. | Semaglutide | — | 2026-04-10 |
| PRECLINICAL | evidence | The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients. | Semaglutide | Glycemic control | 2026-04-10 |
| PRECLINICAL | evidence | Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease. | Semaglutide | — | 2026-04-07 |
| PRECLINICAL | evidence | Once-Weekly Semaglutide in Patients with Cardiovascular-Kidney-Metabolic Syndrome: A Real-World Study. | Semaglutide | — | 2026-04-07 |
| PRECLINICAL | evidence | Semaglutide-Associated Sequential Unilateral Transient Osteoporosis of The Hip: A Case Report. | Semaglutide | — | 2026-04-06 |
| PRECLINICAL | evidence | Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart. | Semaglutide | — | 2026-04-06 |